BillionToOne, Inc.

BillionToOne, Inc. is a next-generation molecular diagnostics company on a mission to create powerful and accurate tests that are accessible to all. The company is headquartered in Menlo Park, California and currently employs 713 full-time employees. The company went IPO on 2025-11-06. The firm's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. The company applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.